Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs and expects significant revenue growth from upcoming approvals, particularly Wainua in ATTR-CM and Olezarsen in SHTG. Ionis' innovative antisense and siRNA technologies target RNA to treat various diseases, with potential multi-billion dollar peak revenue drugs nearing commercial approval.
AstraZenca drug for nerve damage given EU Green light
AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis, a rare disease that damages nerves and leads to disability. The green light is based on a successful phase III trial, showing the drug improved patients' nerve function and quality of life compared to a placebo.
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio.
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Executive Vice President and Chief Development Officer Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer Elizabeth Hougen - Executive Vice President and Chief Financial Officer Eric Swayze - Executive Vice President of Research Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Amy Li - Jefferies Myles Minter - William Blair Yanan Zhu - Wells Fargo Securities Jessica Fye - JPMorgan Allison Bratzel - Piper Sandler Yaron Werber - TD Cowen Jason Gerberry - Bank of America Jay Olson - Oppenheimer Michael Ulz - Morgan Stanley Gary Nachman - Raymond James Salveen Richter - Goldman Sachs Kostas Biliouris - BMO Capital Markets Operator Good morning, and welcome to the Ionis Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
